Meeting
2020 Genitourinary Cancers Symposium
Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).
Authors
Panagiotis J. Vlachostergios
Weill Cornell Medicine, New York, NY
Panagiotis J. Vlachostergios , Sukanya Goswami , Muhammad Junaid Niaz , Charlene Thomas , Paul J. Christos , Joseph Osborne , Shankar Vallabhajosula , Ana M. Molina , Cora N. Sternberg , Sharon Singh , Angela Tan , Amie Patel , David M. Nanus , Neil Harrison Bander , Scott T. Tagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT03042468
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 45)
Abstract #
45
Poster Bd #
B11
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2020 Genitourinary Cancers Symposium
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.
First Author: Michael Philip Sun
Poster
2021 Genitourinary Cancers Symposium
A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
First Author: Michael Sun